LAXISAM Pharmaceuticals
Menu

Pharmacovigilance

A suspected adverse reaction report describes an unwanted change in health that occurred during the use of a medicine. Reports help assess medicine safety and identify new risks. Patients, healthcare professionals, pharmacists and patient representatives may report.

How to report to the manufacturer

pv@laxisampharma.uz

Email sent to pv@laxisampharma.uz is forwarded to the pharmacovigilance mailbox and stored by the email provider outside the Republic of Uzbekistan. Reports may also be sent to the factory’s postal address. Write the medicine name as free text in your message.

254, 1st passage, Usta Shirin Street, Olmazor district, Tashkent 100057, Uzbekistan

Report via the form

Fields marked with an asterisk are the minimum needed to assess a report. Do not enter the patient's full name.

About the reporter
About the patient (at least one field)*

What to include

Please provide four groups of information for an initial assessment. You may report a suspicion even if a connection between the medicine and the reaction has not been established.

  • Reporter: name or initials, qualification (physician, pharmacist, other healthcare professional, patient or representative), country and contact details for follow-up.
  • Patient: initials, age and sex. Do not include the patient’s full name.
  • Medicine: name and batch number. Indicate if any details are unknown.
  • Reaction: describe what happened and when it started.

Additional useful information

Also indicate the report type: adverse reaction, lack of efficacy or medication error. If known, include the dose, treatment start and end dates, other medicines taken and the outcome of the reaction.

How reports are handled

Reports are registered and assessed by the person responsible for pharmacovigilance. Where required, information is forwarded to the Center for Pharmaceutical Products Safety within the applicable timelines, in accordance with the pharmacovigilance legislation of the Republic of Uzbekistan. You may be contacted for further details.

Confidentiality

Patient and reporter information is handled confidentially and used for safety assessment and pharmacovigilance obligations. Include only information needed to assess the report.

Quality complaints

Packaging or appearance issues and suspected falsification can be reported through the same channel: pv@laxisampharma.uz. Include the medicine name, batch number and a description of the concern.

Report directly to the regulator

You may also contact the Center for Pharmaceutical Products Safety directly:

State Institution “Center for Pharmaceutical Products Safety” under the Ministry of Health of the Republic of Uzbekistan

Marketing authorisation holders, medical and pharmaceutical professionals, and members of the public may report adverse reactions.

Regulator address: 100002, Tashkent, 16, K. Umarov passage, Ozod Street.

Personal data

By sending a report, you consent to LAXISAM PHARMACEUTICALS LLC processing the personal data included in it, including health data, exclusively for pharmacovigilance purposes. You also consent to the storage and processing of these data, including on the email provider’s servers outside the Republic of Uzbekistan. Please do not include the patient’s full name; initials, age and sex are sufficient. Data are retained for at least the period required for pharmacovigilance documentation. You may withdraw your consent by emailing pv@laxisampharma.uz.